Cancer Immunotherapy

Phase I/II Trial of AlloMune Cancer System Initiated

Published in Blood Weekly, April 20th, 2000

BioTransplant Inc. (BTRN), Charlestown, Massachusetts, announced that enrollment and treatment has begun in a multi-center Phase I/II trial of the AlloMune Cancer System under an Investigative New Drug for the treatment of therapy-refractory Hodgkin's and non-Hodgkin's lymphoma (NHL).

The company's AlloMune Cancer System is being designed to re-educate the body's immune system to accept foreign cells with the potential to produce powerful anti-tumor effects and minimize the occurrence of severe graft-versus-host disease (GvHD).

The trial is built on the success of a prototype AlloMune System, which has been used at The Massachusetts General Hospital...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2000-04-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry